These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27353034)

  • 1. Ofatumumab-associated acute respiratory manifestations: clinical characteristics and treatment.
    Bonanni A; Bertelli E; Moscatelli A; Lampugnani E; Bodria M; Ravani P; Ghiggeri GM
    Br J Clin Pharmacol; 2016 Oct; 82(4):1146-8. PubMed ID: 27353034
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Albuterol Premedication vs Placebo on the Occurrence of Respiratory Adverse Events in Children Undergoing Tonsillectomies: The REACT Randomized Clinical Trial.
    von Ungern-Sternberg BS; Sommerfield D; Slevin L; Drake-Brockman TFE; Zhang G; Hall GL
    JAMA Pediatr; 2019 Jun; 173(6):527-533. PubMed ID: 31009034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P; Bonanni A; Ghiggeri GM
    BMJ Open; 2017 Mar; 7(3):e013319. PubMed ID: 28314744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
    Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
    Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ofatumumab for rituximab-resistant nephrotic syndrome.
    Basu B
    N Engl J Med; 2014 Mar; 370(13):1268-70. PubMed ID: 24670185
    [No Abstract]   [Full Text] [Related]  

  • 6. Ofatumumab for the treatment of childhood nephrotic syndrome.
    Wang CS; Liverman RS; Garro R; George RP; Glumova A; Karp A; Jernigan S; Warshaw B
    Pediatr Nephrol; 2017 May; 32(5):835-841. PubMed ID: 28213687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    Reagan JL; Castillo JJ
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome.
    Bernard J; Bruel A; Allain-Launay E; Dantal J; Roussey G
    Pediatr Transplant; 2018 Jun; 22(4):e13175. PubMed ID: 29569812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trichomegaly of the eyelashes following treatment with cetuximab.
    Bouché O; Brixi-Benmansour H; Bertin A; Perceau G; Lagarde S
    Ann Oncol; 2005 Oct; 16(10):1711-2. PubMed ID: 15972283
    [No Abstract]   [Full Text] [Related]  

  • 10. Chest physiotherapy for acute wheezing: an inappropriate protocol in a misdiagnosed group of patients.
    Vilaro J; Torres-Castro R; Postiaux G
    Acta Paediatr; 2014 Aug; 103(8):e325-6. PubMed ID: 24702515
    [No Abstract]   [Full Text] [Related]  

  • 11. Chest physiotherapy for acute wheezing episodes: an inappropriate interpretation of the first trial in outpatient infants.
    Castro-Rodriguez JA; Sanchez I
    Acta Paediatr; 2014 Aug; 103(8):e326-7. PubMed ID: 24852268
    [No Abstract]   [Full Text] [Related]  

  • 12. Ofatumumab (Arzerra) for CLL.
    Med Lett Drugs Ther; 2010 Jun; 52(1341):51-2. PubMed ID: 20585286
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
    Ewer MS; Tan-Chiu E
    J Clin Oncol; 2007 Dec; 25(34):5532-3; author reply 5533-4. PubMed ID: 18048835
    [No Abstract]   [Full Text] [Related]  

  • 14. Trastuzumab--mechanism of action and use.
    Mir O; Berveiller P; Pons G
    N Engl J Med; 2007 Oct; 357(16):1664-5; author reply 1665-6. PubMed ID: 17948347
    [No Abstract]   [Full Text] [Related]  

  • 15. Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?
    Morabito A; Piccirillo MC; De Maio E; Di Maio M; Perrone F
    J Clin Oncol; 2009 Sep; 27(27):e123; author reply e124-5. PubMed ID: 19687322
    [No Abstract]   [Full Text] [Related]  

  • 16. [Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer].
    Iglesias P; Soria A; Díez JJ
    Med Clin (Barc); 2015 Sep; 145(6):264-8. PubMed ID: 25851909
    [No Abstract]   [Full Text] [Related]  

  • 17. Ofatumumab approved for advanced CLL.
    Traynor K
    Am J Health Syst Pharm; 2009 Dec; 66(23):2062. PubMed ID: 19923303
    [No Abstract]   [Full Text] [Related]  

  • 18. Trastuzumab for early breast cancer.
    Thorat M
    Lancet; 2006 Jan; 367(9505):108. PubMed ID: 16413867
    [No Abstract]   [Full Text] [Related]  

  • 19. Trastuzumab.
    Nurs Times; 2006 Mar 7-13; 102(10):33. PubMed ID: 16548266
    [No Abstract]   [Full Text] [Related]  

  • 20. Alemtuzumab for treatment of lymphoproliferative disorders.
    Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.